Search

Displaying results 3691 - 3700 of 10000 in total
  1. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

    Synonyms: 1-(2-(Benzylcarbamoyl)ethyl)-2-isonicotinoylhydrazine, N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazineCategories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … Lacidipine is a highly lipophilic molecule that interacts with the biological membranes.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: LACIPIL TABLET 4 mg, LACIPIL 4 MG FILM KAPLI TABLET, 14 ADET
  3. Drug

    Bethanidine

    go.drugbank.com/drugs/DB00217
    Approved

    A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.

    Categories: Adrenergic alpha-2 Receptor AgonistsSynonyms: N,N'-dimethyl-N''-(phenylmethyl)-guanidine
  4. Drug

    Aluminum acetate

    go.drugbank.com/drugs/DB14518
    ApprovedInvestigational

    Mixtures: ZISUAL-C, SPERTI PREPARATION HProducts: ACID MANTLE® N LOCION., ACETALIFE®
  5. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_. … The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001].

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  6. Drug

    Clofibrate

    go.drugbank.com/drugs/DB00636
    ApprovedWithdrawn

    A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: 2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester, 2-(p-Chlorophenoxy)-2-methylpropionic acid ethyl ester
  7. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

    Synonyms: THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-, ((2R,3R,4R,5R)-4-ACETOXY-5-(5-AMINO-2-OXO-THIAZOLO(4,5-D)PYRIMIDIN-3-YL)-2-(HYDROXYMETHYL)TETRAHYDROFURAN-3-YL) ACETATE
  8. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses. … The vaccine consists of a string of 18 HIV-derived major histocompatibility complex (MHC) Class II restricted epitopes, each separated by a spacer designed to optimize potency.

  9. Drug

    Sibrotuzumab

    go.drugbank.com/drugs/DB06474
    Investigational

    Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

  10. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

    Categories: Heterocyclic Compounds, 2-Ring